Mayo Clinic

Anumana develops AI algorithms that analyze ECG data to support early diagnosis of cardiovascular conditions. Its platform aims to enhance cardiac care by assisting healthcare professionals in identifying potential heart issues, improving patient outcomes throughout the continuum of cardiovascular care.

Myosin Therapeutics is a biopharmaceutical company focused on developing novel medications that target cellular motor proteins. It leverages molecular machines that convert energy into mechanical work inside cells to create therapies aimed at treating central nervous system disorders and other diseases, including cancer. The company concentrates on advancing pharmacotherapies that modulate motor protein activity to impact disease pathways and address significant unmet medical needs.

Delfina operates a data-driven prenatal care system designed to enhance maternal and infant safety during pregnancy. The company employs machine learning models to optimize interventional workflows and create personalized care plans based on patient risk factors, thereby facilitating early interventions and improving provider efficiency. This approach aims to deliver equitable and cost-effective pregnancy care within the healthcare industry.

Scaled Insights Inc. is a Toronto-based company specializing in artificial intelligence software that focuses on analyzing human speech to facilitate accessible communication. Established in 2015, the company has developed a unique Behavioral AI technology aimed at improving interactions in various industries, including healthcare, fintech, insurtech, and human resources. Its offerings enable users to manage insurance claims, align financial advisors with clients, identify high performers, and foster better communication regarding health and wellness. The software is particularly beneficial for clinicians, allowing them to understand patient personalities and provide personalized coaching to promote healthier behaviors. By analyzing complex human behavior data, Scaled Insights helps organizations optimize operations and make informed, data-driven decisions to enhance patient outcomes and reduce costs. Additionally, the company has an office in Leeds, United Kingdom, further expanding its operational reach.

Jupiter Bioventures is a venture builder company dedicated to de-risking early-stage therapeutic projects. It operates by evaluating opportunities through a specific set of investment criteria and providing initial seed capital to founders. This approach enables the growth of innovative projects in the biotechnology sector, supporting entrepreneurs as they navigate the challenges of early development. By focusing on early-stage initiatives, Jupiter Bioventures aims to foster advancements in therapeutic solutions while minimizing the inherent risks associated with new ventures.

Aignostics GmbH is a Berlin-based company founded in 2018 that specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics, employing patented technology to reverse-engineer conventional AI systems, thereby addressing their “black-box” limitations. Aignostics' platform generates explainable diagnostic results presented as precise heatmaps and image overlays, which facilitate the verification process for pathologists. This capability is crucial in ensuring accurate diagnoses, particularly in the context of discovering and validating biomarkers for cancer and other complex diseases. By improving the understanding of tissue-based biomarkers, Aignostics aims to significantly advance the diagnosis and treatment of various conditions, thereby supporting the broader goals of precision medicine and drug development.

Clarapath specializes in automating laboratory processes for pathology. Its flagship product, Section Star, streamlines microtomy using a tape transfer method. The company offers routine histology services, digital pathology solutions, and quantitative image analysis. Serving academic researchers, clinical labs, and physicians, Clarapath aims to enhance lab medicine quality, safety standards, and throughput while reducing costs.

Endogenex develops a novel endoscopic procedure using pulsed electric fields to regenerate the duodenal mucosa, aiming to improve glycemic control in patients with Type 2 Diabetes.

JOGO Health is a virtual care company that specializes in digital therapeutics aimed at treating pain, neuromuscular conditions, and pelvic floor disorders. Utilizing clinically proven digital interventions, the company develops an AI-driven mobile app paired with wearable sensors that deliver tailored treatment protocols. These offerings include games and exercises designed for muscle relaxation, movement coordination, and neuromuscular reeducation, all leveraging the brain's neuroplasticity. By enhancing patient adherence to rehabilitation programs, JOGO Health enables healthcare providers to achieve improved health outcomes for conditions such as chronic pain, stroke recovery, and pelvic health issues.

AccuLine is a digital health company dedicated to early detection of coronary artery disease. It develops CORA, a smart, accurate, and user-friendly exam designed to replace traditional ECG stress tests, enabling healthcare providers to prevent heart attacks more effectively.

Qlaris Bio is a clinical-stage biotechnology company based in Wellesley, Massachusetts, founded in 2017. The company specializes in developing innovative therapies for serious and debilitating ophthalmic diseases, with a focus on addressing episcleral venous pressure (EVP), a significant component of intraocular pressure (IOP). Qlaris Bio's lead therapy, QLS-101, aims to reduce IOP, thereby mitigating the risk of blindness in conditions such as Primary Open Angle Glaucoma and Normal Tension Glaucoma. The company also targets other high unmet need conditions related to disturbances in intraocular pressure, including a progressive pediatric rare disease with limited effective therapies.

PinkDx is a biotechnology company specializing in women's health. It develops molecular tests to improve diagnostic outcomes for women with vague gynecological cancer symptoms, offering alternatives to invasive procedures. This enables more comfortable and efficient resolution of health concerns, providing timely and positive impacts on patients' lives.

Collaborative Robotics is a team of innovators and builders redefining the future of human-robot interaction. A future in which robots are trustworthy extensions of the environment. They operate, adapt, and react in response.

UpDoc is a technology-enabled services firm that offers the world's first unique conversational AI platform for autonomous prescription management.

vMocion, LLC is a Scottsdale, Arizona-based company that specializes in developing a unique platform known as vMocion’s 3v™ Platform, which leverages galvanic vestibular stimulation (GVS) technology to enhance virtual and augmented reality experiences. Established in 2015, vMocion holds exclusive global licensing rights to Mayo Clinic's GVS patents and algorithms for use in media and entertainment. The platform enables the conversion of 2D and 3D content into synchronized three-dimensional movement data, creating a realistic sensation of motion for users. This technology can be integrated into various devices, including head-mounted displays, smartphones, and televisions, and is designed to improve user experience by reducing virtual reality sickness. vMocion aims to revolutionize how media and entertainment industries incorporate motion sensations into their virtual reality offerings.

Abridge is a healthcare technology company that uses generative AI to automate transcription and summarization of medical conversations. The platform turns patient-clinician discussions into structured clinical notes in real time and integrates with electronic health record systems. By reducing manual note-taking, it helps clinicians capture key details while producing clear summaries for patients, and ensures documentation is added to patient records. Abridge emphasizes data security and patient privacy, complies with healthcare regulations, and provides a customizable interface aligned with clinical workflows and patient needs.

Nucleus RadioPharma is a company focused on enhancing the accessibility of radiopharmaceuticals for cancer patients. It specializes in developing innovative technologies aimed at modernizing the clinical development, manufacturing, and supply chain processes associated with radiopharmaceutical therapies. By streamlining these aspects, Nucleus RadioPharma seeks to improve the delivery of novel treatments, thereby enabling healthcare professionals to more effectively diagnose and treat various cancer diseases.

InfoBionic, Inc., incorporated in 2011 and based in Lowell, Massachusetts, specializes in remote patient monitoring technologies, particularly focusing on cardiac arrhythmia detection. The company has developed the MoMe System, a cloud-based platform that allows for continuous monitoring of electrocardiogram, respiration, and motion data. This wireless system streamlines the remote patient monitoring process, enhancing both clinical efficiency and patient care by enabling healthcare providers to access patient data anytime and anywhere. InfoBionic's innovative approach aims to transform the economics of cardiac diagnostic services, benefiting both physicians and patients through improved detection and treatment of cardiac complications.

AccuLine is a digital health company dedicated to early detection of coronary artery disease. It develops CORA, a smart, accurate, and user-friendly exam designed to replace traditional ECG stress tests, enabling healthcare providers to prevent heart attacks more effectively.

The Contract Network develops a digital collaborative platform designed to accelerate clinical trial processes. Its platform focuses on expediting contract negotiations, ensuring compliance, and streamlining clinical trial agreement negotiations.

Collaborative Robotics is a team of innovators and builders redefining the future of human-robot interaction. A future in which robots are trustworthy extensions of the environment. They operate, adapt, and react in response.

Basys.ai streamlines healthcare administration by automating prior authorization and utilization management processes for health plans using an AI-based platform. This proprietary system digitizes payer policies via machine learning, reducing implementation timelines significantly.

EBAMed develops a non-invasive ultrasound-based device to monitor and treat heart motion using proton beams. Founded in 2018, the company is based in Geneva, Switzerland.

AccurKardia is an innovative company specializing in ECG-led diagnostics software. It transforms ECG data into a powerful tool to improve patient outcomes globally, with initial applications in cardiology. The company offers AccurECG™, an FDA-cleared Class II software as a medical device (SaMD) for automated, near real-time ECG interpretation. Its AI-driven hyperkalemia detection solution, AK+ Guard™, received FDA Breakthrough Device Designation.

Medivis is a developer of advanced medical imaging technology that utilizes augmented reality and artificial intelligence to enhance surgical operations. The company's innovative platform enables physicians to overlay holographic images directly onto patients during procedures, facilitating precise decision-making in the operating room. By integrating these technologies, Medivis aims to improve surgical outcomes and streamline the workflow for healthcare professionals, ultimately advancing the field of surgical navigation.

MediView, LLC is a medical device company based in Cleveland, Ohio, that specializes in developing augmented reality surgical navigation systems aimed at enhancing surgical processes for healthcare providers. Founded in 2017, the company focuses on creating advanced technologies for surgical navigation, particularly for the ablation and biopsy of cancerous tumors. MediView's flagship product, MediView, utilizes real-time, fused-holographic visualization to enable surgeons to navigate procedures with greater accuracy and efficacy. This innovative approach allows for enhanced examination of patients through augmented reality 3D visualization, facilitating improved surgical outcomes and supporting remote collaboration among healthcare professionals.

Lucem Health is a company that specializes in remote diagnostics through an innovative platform that connects patient telemetry and biosensing devices with artificial intelligence algorithms. The platform is designed to facilitate data ingestion, orchestration, and connectivity, which enhances continuous care for patients while allowing them greater control over their health. Additionally, Lucem Health supports the development and deployment of clinical AI models, enabling healthcare providers to integrate AI-generated insights into their workflows. This capability allows clinicians to improve care delivery by better understanding the impact of these insights on patient outcomes. Overall, Lucem Health aims to enhance the effectiveness of healthcare through advanced technology and data-driven solutions.

Mediwhale is a healthcare company focused on preventive medicine through innovative AI technology. The company has developed a unique AI screening platform that utilizes retinal scans for non-invasive risk assessments and diagnoses related to cardiovascular, renal, metabolic health, and eye diseases. Mediwhale's platform includes RetiCVD® for cardiovascular disease risk assessment, RetiCKD® for chronic kidney disease risk assessment, and RetiEYE® for detecting referable eye diseases. These tools have been clinically validated through collaborations with medical institutions across multiple countries and are recognized for their accuracy in predicting health risks before symptoms appear.

Cadence Neuroscience develops implantable medical device therapies for epilepsy, central pain, and other neurological disorders. Founded in 2017 and based in Redmond, Washington, the company pursues core technology developed at Mayo Clinic that is being evaluated clinically. The device detects brain signals and delivers electrical stimulation to modulate neural circuits, enabling personalized brain stimulation to improve seizure control relative to existing protocols.

Healium is a technology company that develops mental fitness tools and immersive, bio-data-driven experiences to support self-management of anxiety, sleep issues, burnout, and overall well-being. The platform links real-time biometric data from wearables such as heart rate and brain activity via EEG headbands to personalized video or VR assets, producing reactive media escapes controlled by the user’s physiology. By integrating wearable devices and sensors, Healium delivers data-driven content that adapts to the user in real time, aiming to reduce anxiety, improve mood, and build resilience for individuals and organizations. Peer-reviewed studies have reported rapid mood benefits and anxiety reduction in as little as four minutes.

R-Zero specializes in smart building technology, providing real-time insights to optimize indoor spaces. Their solutions include Indoor Air Quality (IAQ) monitoring, energy-efficient HVAC systems, space utilization sensors, and occupancy-based controls. The platform is user-friendly, secure, scalable, and helps prepare buildings for future challenges.

Acorai develops a non-invasive heart failure monitoring platform centered around direct intracardiac pressure monitoring. Its patented technology combines sensor technologies and machine learning to enable accurate, cost-efficient care, reducing re-hospitalization and mortality rates.

Nucleus RadioPharma is a company focused on enhancing the accessibility of radiopharmaceuticals for cancer patients. It specializes in developing innovative technologies aimed at modernizing the clinical development, manufacturing, and supply chain processes associated with radiopharmaceutical therapies. By streamlining these aspects, Nucleus RadioPharma seeks to improve the delivery of novel treatments, thereby enabling healthcare professionals to more effectively diagnose and treat various cancer diseases.

Genomadix specializes in developing molecular tests for infectious diseases, precision medicine, and water safety. Its innovative platform and portable analyzer use PCR technology to deliver swift, accurate test results outside traditional healthcare settings.

Senda Biosciences, founded in 2017 by David Kolesky, Ignacio Martinez, and John Casey in Cambridge, Massachusetts, focuses on developing therapeutic applications for innovative treatments of human diseases. The company specializes in studying the molecular relationships between bacterial, botanical, and human cells to understand how these interactions influence health and disease. By gaining insights into these interspecies connections, Senda Biosciences aims to create novel categories of medicines and delivery methods, providing medical professionals with new tools to combat various illnesses.

Founded in 2017, Diagnostic Robotics develops an artificial intelligence-driven robot for healthcare insurers, providers, and patients. Its signal-agnostic AI system enables predictive analytics models to optimize clinical program performance, reduce costs, and improve care.

Midday is an app that leverages AI, sensor technology, and digital therapeutics to support women on their menopause journey using personalized insights that illuminate what is happening physically and emotionally during menopause, providing the right intervention at the right time to manage menopause symptoms and promote healthy aging.

Ordr, Inc. is a cybersecurity company based in Santa Clara, California, established in 2015. It specializes in securing Internet of Things (IoT) devices across various sectors, including healthcare, manufacturing, retail, public venues, and logistics. Ordr's platform utilizes advanced machine learning and deep packet inspection to autonomously identify, classify, and monitor devices within an enterprise network. Its Systems Control Engine, a software-as-a-service solution, maps all connected devices, assesses their risk and behavior, and enforces traffic flow and access policies to enhance security. Organizations worldwide rely on Ordr for real-time asset inventory, risk management, compliance, and to streamline IT initiatives.

Olive Diagnostics is a company that has developed an innovative passive urine analysis sensor designed to enhance early disease detection and chronic disease management. This sensor, which can be easily mounted to any toilet, utilizes spectroscopy combined with artificial intelligence-based analytics to monitor the urine stream. By continuously collecting and analyzing health data, the device provides users with real-time health alerts that promote awareness of their bodily functions. The technology not only supports individual health management but also offers valuable insights for pharmaceutical and contract research organizations to track drug compliance and usage. With its focus on proactive health monitoring, Olive Diagnostics aims to make urine lab services accessible even in nonindustrial nations, thereby transforming personal health care through advanced, continuous biomarker tracking.

Karkinos Healthcare is a technology-driven oncology-focused managed health care platform that supports early detection and diagnosis of common cancers and aims to extend cancer care to patients at home. The platform connects patients with healthcare providers, technicians, researchers, and oncologists to enable personalized insights, precision medicine, and coordinated care across the care continuum, creating an accessible and effective cancer care ecosystem.

Vyriad, Inc. is a clinical-stage biotechnology company focused on developing oncolytic virotherapy for cancer. Its approach uses engineered viruses, including vesicular stomatitis virus and measles virus platforms, to selectively infect and destroy cancer cells while sparing normal tissue and to stimulate anti-tumor immune responses. The company also works on diagnostic and theranostic tests to predict responses to immunovirotherapy. Vyriad collaborates with external research foundations and industry partners, including a strategic agreement with Regeneron Pharmaceuticals. The company leverages decades of research from Mayo Clinic and the University of Miami in its programs. Vyriad was established in 2012 and is based in Rochester, Minnesota.

Theator Inc., founded in 2018, develops an AI-powered surgical intelligence platform. It uses computer vision to analyze video data from surgeries, providing surgeons with tools to review and improve their performance.

Collider activates, connects, and empowers early-stage entrepreneurs in Rochester, Minnesota.

Medically Home Group, Inc. is a Boston-based company that specializes in providing a virtual hospital program designed to deliver in-home medical care services. Founded in 2016, the company focuses on shifting medical care from traditional hospital settings to patients' homes, particularly for those with serious or complex illnesses such as heart failure, pneumonia, and respiratory infections. Medically Home's technology-enabled platform connects patients with caregivers, facilitating ongoing monitoring and communication. This system allows patients and their families to access a centralized medical command center, which offers on-demand acute medical care management, ensuring that necessary medical support is available in a more comfortable and familiar environment.

The Patient Company designs and manufactures SimPull, an automated lateral patient transfer device. SimPull aims to protect clinicians from injuries, shorten transfer times, and eliminate waste associated with disposable components of competing products. Founded in 2019 and based in Grand Rapids, Michigan, the company also maintains operations in Scottsdale, Arizona. The motorized device is fully automated and can be operated by a single care team member, enabling safe, efficient transfers with automated management while reducing risk to staff and supporting respectful patient handling.

Tympany Medical is a company focused on advancing minimally invasive ear surgeries through innovative technology. It has developed a specialized ear surgery device that facilitates sterile endoscopy in the field of otolaryngology. This device addresses the challenges associated with traditional endoscopes, enhancing usability and flexibility for surgeons. By enabling effective endoscopic visualization, Tympany's technology allows surgeons to perform complex ear procedures while preserving their two-handed operating technique. The company's mission is to reduce the need for unnecessary mastoidectomies and improve surgical outcomes for patients undergoing ear surgery.

SimBioSys is focused on advancing cancer care through its innovative Computational Microscope, which merges advanced simulation techniques with a wide array of experimental datasets. This technology enables researchers to gain insights into the cancer microenvironment, allowing them to observe tumor behavior, including cell phenotypes and interactions with surrounding tissues. By creating personalized virtual tumors from comprehensive diagnostic data, SimBioSys facilitates computational scenario analysis that enhances doctors' understanding of individual cases. This approach aims to improve decision-making and patient experiences in the realm of oncology, ultimately transforming cancer treatment.

Founded in 2019, TripleBlind operates an online platform enabling entities to collaborate on sensitive data and algorithms without compromising privacy. Its software-only solution, delivered via API, focuses on healthcare and financial services, supporting various data types and cloud platforms. Backed by Accenture, General Catalyst, and Mayo Clinic, TripleBlind ensures compliance with HIPAA and GDPR.

Laplace develops transcatheter tricuspid valve technology, enhancing life expectancy and improving quality of life for global patients with tricuspid regurgitation through a minimally invasive procedure.

JOGO Health is a virtual care company that specializes in digital therapeutics aimed at treating pain, neuromuscular conditions, and pelvic floor disorders. Utilizing clinically proven digital interventions, the company develops an AI-driven mobile app paired with wearable sensors that deliver tailored treatment protocols. These offerings include games and exercises designed for muscle relaxation, movement coordination, and neuromuscular reeducation, all leveraging the brain's neuroplasticity. By enhancing patient adherence to rehabilitation programs, JOGO Health enables healthcare providers to achieve improved health outcomes for conditions such as chronic pain, stroke recovery, and pelvic health issues.

R-Zero specializes in smart building technology, providing real-time insights to optimize indoor spaces. Their solutions include Indoor Air Quality (IAQ) monitoring, energy-efficient HVAC systems, space utilization sensors, and occupancy-based controls. The platform is user-friendly, secure, scalable, and helps prepare buildings for future challenges.

Senda Biosciences, founded in 2017 by David Kolesky, Ignacio Martinez, and John Casey in Cambridge, Massachusetts, focuses on developing therapeutic applications for innovative treatments of human diseases. The company specializes in studying the molecular relationships between bacterial, botanical, and human cells to understand how these interactions influence health and disease. By gaining insights into these interspecies connections, Senda Biosciences aims to create novel categories of medicines and delivery methods, providing medical professionals with new tools to combat various illnesses.

Helix is a prominent population genomics company that focuses on the convergence of clinical care, research, and genomics. Its comprehensive platform assists health systems, life sciences companies, and payers in advancing genomic research and integrating genomic data into clinical practice. Helix operates one of the world's largest CLIA/CAP-certified next-generation sequencing labs and utilizes its proprietary Exome+ assay to support various aspects of population genomics, including participant recruitment, disease screening, result reporting, and both basic and translational research.

Medically Home Group, Inc. is a Boston-based company that specializes in providing a virtual hospital program designed to deliver in-home medical care services. Founded in 2016, the company focuses on shifting medical care from traditional hospital settings to patients' homes, particularly for those with serious or complex illnesses such as heart failure, pneumonia, and respiratory infections. Medically Home's technology-enabled platform connects patients with caregivers, facilitating ongoing monitoring and communication. This system allows patients and their families to access a centralized medical command center, which offers on-demand acute medical care management, ensuring that necessary medical support is available in a more comfortable and familiar environment.

Adaptive Phage Therapeutics, Inc. is a clinical-stage company focused on addressing the global challenge posed by multi-drug resistant (MDR) pathogenic bacteria. Founded in 2016 and headquartered in Gaithersburg, Maryland, the company offers therapeutic solutions utilizing its PhageBank, a comprehensive collection of bacteriophages—viruses that specifically target harmful bacteria. Through an advanced system for matching these phages to the unique bacterial infections of patients, Adaptive Phage Therapeutics aims to enable medical researchers to create effective treatments that can detect and combat MDR infections.

Anumana develops AI algorithms that analyze ECG data to support early diagnosis of cardiovascular conditions. Its platform aims to enhance cardiac care by assisting healthcare professionals in identifying potential heart issues, improving patient outcomes throughout the continuum of cardiovascular care.

Anumana develops AI algorithms that analyze ECG data to support early diagnosis of cardiovascular conditions. Its platform aims to enhance cardiac care by assisting healthcare professionals in identifying potential heart issues, improving patient outcomes throughout the continuum of cardiovascular care.

Glooko develops a remote patient-monitoring platform for individuals with diabetes. It integrates with diabetes devices, fitness wearables, and activity trackers to capture data and provide reports, aiming to drive behavior change and improve health outcomes. The platform facilitates communication between patients and healthcare providers, enhancing care. Glooko is available on Android and iOS.

Nuvolo Technologies Corporation offers a cloud-based enterprise asset management platform designed to support the lifecycle management of assets in various sectors, including healthcare, manufacturing, and facilities management. Founded in 2013 and headquartered in Paramus, New Jersey, Nuvolo innovates on the ServiceNow platform to provide a user-friendly experience for mobile and online users. The company’s solutions encompass implementation, support, tracking, reporting, and analytics, aimed at optimizing operational efficiency and improving asset management. Nuvolo also emphasizes security, workflow automation, and accurate inventory data, making it a comprehensive choice for businesses looking to enhance their asset management capabilities. With additional offices in London, Sofia, and Pune, Nuvolo maintains a global presence through strategic partnerships with firms such as KPMG and Unisys.

Founded in 2019, TripleBlind operates an online platform enabling entities to collaborate on sensitive data and algorithms without compromising privacy. Its software-only solution, delivered via API, focuses on healthcare and financial services, supporting various data types and cloud platforms. Backed by Accenture, General Catalyst, and Mayo Clinic, TripleBlind ensures compliance with HIPAA and GDPR.

Founded in 2017, Diagnostic Robotics develops an artificial intelligence-driven robot for healthcare insurers, providers, and patients. Its signal-agnostic AI system enables predictive analytics models to optimize clinical program performance, reduce costs, and improve care.

nference is a technology company that develops AI-based software platforms for transforming biomedical knowledge. It synthesizes structured and unstructured data from various sources, offering real-time insights through neural networks. The company provides services in drug discovery, lifecycle management, and precision medicine.

Adaptive Phage Therapeutics, Inc. is a clinical-stage company focused on addressing the global challenge posed by multi-drug resistant (MDR) pathogenic bacteria. Founded in 2016 and headquartered in Gaithersburg, Maryland, the company offers therapeutic solutions utilizing its PhageBank, a comprehensive collection of bacteriophages—viruses that specifically target harmful bacteria. Through an advanced system for matching these phages to the unique bacterial infections of patients, Adaptive Phage Therapeutics aims to enable medical researchers to create effective treatments that can detect and combat MDR infections.

Ordr, Inc. is a cybersecurity company based in Santa Clara, California, established in 2015. It specializes in securing Internet of Things (IoT) devices across various sectors, including healthcare, manufacturing, retail, public venues, and logistics. Ordr's platform utilizes advanced machine learning and deep packet inspection to autonomously identify, classify, and monitor devices within an enterprise network. Its Systems Control Engine, a software-as-a-service solution, maps all connected devices, assesses their risk and behavior, and enforces traffic flow and access policies to enhance security. Organizations worldwide rely on Ordr for real-time asset inventory, risk management, compliance, and to streamline IT initiatives.

Securisyn Medical manufactures and supplies oxygen delivery systems for mechanically ventilated patients in critical care settings. Its innovative airway stabilization system, featuring a ribbed endotracheal tube and interlocking stabilizer, enhances patient safety by preventing unplanned extubation and reducing healthcare costs.

Progentec Diagnostics, Inc. is a company focused on developing innovative diagnostic tests for managing systemic lupus erythematosus (SLE). Established in 2015 and headquartered in Oklahoma City, Oklahoma, the company has created the aiSLE DX platform, which offers tools like a flare prediction score to measure disease activity in SLE patients and an early diagnostic test for lupus. Progentec integrates advanced technology and collaborates with research institutions globally, aiming to address significant unmet needs in diagnostic interventions. The company's mission centers on improving disease management and reducing disease incidence through enhanced screening and early detection.

nference is a technology company that develops AI-based software platforms for transforming biomedical knowledge. It synthesizes structured and unstructured data from various sources, offering real-time insights through neural networks. The company provides services in drug discovery, lifecycle management, and precision medicine.

Novome Biotechnologies, Inc. is a biotechnology company specializing in the engineering of gut bacteria to create innovative therapies for chronic diseases. Established in 2015 and located in South San Francisco, California, Novome has developed a pioneering platform for the controlled colonization of the gut with genetically engineered microbial medicines (GEMMs). This platform allows for the precise delivery of therapeutic activities aimed at treating conditions such as hyperoxaluria, with a focus on creating a bacterial strain that can degrade oxalate to help prevent kidney stone formation. The company is also expanding its synthetic biology capabilities to explore additional therapeutic indications, aiming to improve long-term health outcomes for patients through its living therapeutics.

Elysium Health, Inc., established in 2014 and headquartered in New York, specializes in the development and sale of health supplements. The company focuses on two primary areas: cellular health and optimization, and long-term brain health. It offers a proprietary formulation of natural compounds, designed to support overall well-being at the cellular level, which is sold directly to consumers via its online platform. Additionally, Elysium provides a biological age testing solution.

HuidaGene Therapeutics Co., Ltd., established in 2018, is a Shanghai-based biotechnology company specializing in the research and development of gene therapies for single-gene disorders and neurodegenerative diseases. The company employs its proprietary CRISPR-based, AI-driven HG-PRECISE platform to create potentially curative treatments. HuidaGene's clinical pipeline includes therapies for RPE65-associated retinal disease (HG004), neovascular age-related macular degeneration (nAMD) (HG202), MECP2 duplication syndrome (HG204), and Duchenne muscular dystrophy (DMD) (HG302). Additionally, the company has preclinical programs focused on therapies for amyotrophic lateral sclerosis (ALS) and Alzheimer's disease.

NewCompliance is a healthcare technology company focused on enhancing the quality and safety of medical care through innovative solutions. The company collaborates with industry leaders such as Stryker, Medtronic, Skytron, and Philips to provide interoperable IT platforms. Its flagship product, the ACTIQ platform, delivers predictive dashboarding and analytics, offering real-time feedback and intelligent management information to healthcare providers. This web-based software is designed to support caregivers across various departments, including surgery, emergency care, and intensive care. By optimizing safety, efficiency, and patient satisfaction, NewCompliance aims to transform the surgical patient journey and improve overall healthcare delivery.

FundamentalVR have been working with leading pharmaceutical companies to combine virtual and mixed reality with haptic feedback using their ‘FeelRealVR’ platform to create simulated surgical procedures to help educate and train healthcare professionals. The company works at the nexus of haptics, machine learning, and immersive technologies (XR). FundamentalVR was established in 2012 by Chris Scattergood in London, England.

AtriAN Medical is an Irish medical device company based in Galway, a prominent center for medical technology innovation. The company is focused on commercializing advanced technology developed at the Mayo Clinic in the United States. AtriAN specializes in a medical device designed to treat atrial fibrillation by employing micro Pulsed Electric Fields (mPEF). This innovative approach selectively ablates hyperactive tissue while preserving surrounding myocardium, minimizing damage to the heart muscle. Utilizing a catheter, AtriAN's device delivers short pulses of electrical energy directly to the problematic areas, offering a targeted treatment option that enhances patient safety and outcomes.

Cadence Neuroscience develops implantable medical device therapies for epilepsy, central pain, and other neurological disorders. Founded in 2017 and based in Redmond, Washington, the company pursues core technology developed at Mayo Clinic that is being evaluated clinically. The device detects brain signals and delivers electrical stimulation to modulate neural circuits, enabling personalized brain stimulation to improve seizure control relative to existing protocols.

Eko Health is a leading digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others. For more information visit www.ekohealth.com.

Qlaris Bio is a clinical-stage biotechnology company based in Wellesley, Massachusetts, founded in 2017. The company specializes in developing innovative therapies for serious and debilitating ophthalmic diseases, with a focus on addressing episcleral venous pressure (EVP), a significant component of intraocular pressure (IOP). Qlaris Bio's lead therapy, QLS-101, aims to reduce IOP, thereby mitigating the risk of blindness in conditions such as Primary Open Angle Glaucoma and Normal Tension Glaucoma. The company also targets other high unmet need conditions related to disturbances in intraocular pressure, including a progressive pediatric rare disease with limited effective therapies.

Safely Health operates an online platform designed to promote safe sexual practices by enabling users to import their test results and verify their STD and COVID-19 status. Founded in 2015 and based in Los Angeles, the company aims to create a trusted, private, and secure environment for individuals seeking to share their health information with potential partners. Safely Health is not just an app but a comprehensive healthcare initiative that collaborates with leading healthcare organizations, including Quest and Labcorp, as well as public health entities like the CDC. By partnering with nonprofit organizations, influencers, and social media platforms, Safely Health seeks to empower users to take control of their sexual health and reduce the spread of STDs, ultimately fostering a safer and more enjoyable dating experience.

GYANT is a digital front door solution for health systems that leverages artificial intelligence to enhance patient navigation to appropriate care settings and in-network resources. The company's platform utilizes natural language processing to understand patients' needs, guiding them throughout their healthcare encounters. By streamlining digital patient journeys, GYANT aims to capture new patients and efficiently serve existing ones while driving process automation within healthcare enterprises. This innovative approach not only improves patient engagement but also enhances care utilization, ultimately leading to reduced costs and time savings for healthcare providers.

Pendulum Therapeutics is a biotechnology company specializing in microbiome-targeted therapies. Founded in 2013 by experts in microbiology, biochemistry, computational science, and clinical research, the company develops evidence-based medical probiotics to manage chronic illnesses, with a focus on type 2 diabetes. Its flagship product, Pendulum Glucose Control, has demonstrated efficacy in lowering blood sugar spikes and reducing A1C levels in clinical trials.

Giblib is a California-based company founded in 2015 and headquartered in Los Angeles. It operates an online video community platform that serves as a resource for medical education, akin to a streaming service for surgical knowledge. The platform allows surgeons to share and access a curated collection of surgical videos and medical lectures across various specialties. By indexing surgical procedures and creating educational content, Giblib provides medical students and practitioners with valuable insights into surgical techniques and medical practices from experienced professionals.

StemoniX Inc. is a biotechnology company that specializes in stem cell technologies aimed at advancing drug discovery and personalized medicine. Founded in 2014 and headquartered in Minneapolis, Minnesota, with an additional office in La Jolla, California, StemoniX offers a proprietary platform that facilitates the creation and scaling of human tissue derived from stem cells. This platform supports the 3-D printing of living cells for various applications, including research into heart disease, dementia, breast cancer, autism, and ALS. By operationalizing human-induced pluripotent stem cell (iPSC) disease models at scale, StemoniX enhances the efficiency of neurotoxicity research and drug screening, enabling scientists to conduct more effective studies with improved outcomes.

Caraway Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that focuses on developing innovative treatments for neurodegenerative diseases by modulating mitophagy and autophagy. The company aims to address the degradation of toxic cellular components, which is a key factor in various neurodegenerative conditions, including Parkinson's disease and amyotrophic lateral sclerosis. By leveraging an understanding of critical neural pathways, Caraway Therapeutics seeks to discover and develop novel small molecules that can restore cellular balance and improve lysosomal function. Founded in 2018 and initially known as Rheostat Therapeutics, Inc., the company rebranded in 2019 to reflect its commitment to finding effective therapies for patients affected by these debilitating diseases.

Marigold Health operates a social network community platform that provides AI-augmented chat support groups designed to assist individuals with behavioral health needs. By facilitating anonymous text-based group therapies, the company enables patients dealing with mental health and substance use conditions to connect and support one another. These support groups are complemented by the involvement of recovery coaches who help participants formulate personalized recovery plans. Marigold Health partners with treatment providers and managed care organizations within the Medicaid market, aiming to enhance patient engagement while allowing care teams to manage increased capacity effectively. Through its innovative approach, the company offers on-demand, stigma-free support for individuals seeking to improve their mental health.

Ambient Clinical Analytics, Inc. is a healthcare technology company specializing in data assimilation, communication, and analytics for clinical decision support. Based in Rochester, Minnesota, the company develops tools tailored for use in intensive care units, operating rooms, and emergency departments. Its flagship product, AWARE, integrates with various electronic health record systems and bedside monitors to deliver critical patient information on a unified dashboard. Additionally, Ambient offers the Mayo Clinic YES Board, a multi-patient management tool that enhances situational awareness and streamlines patient flow. The company also provides specialized solutions such as Sepsis DART for real-time sepsis detection and the Ventilator-Induced Lung Injury Sniffer for monitoring ventilator patients. Furthermore, the Synthesis Platform serves as an integration hub for AWARE and the Mayo Clinic tools, facilitating seamless data exchange. Ambient Clinical Analytics was founded in 2013 and focuses on improving patient outcomes while reducing healthcare costs through innovative technology.

Vineti, Inc. is a technology company focused on advancing the development and delivery of personalized therapies, particularly in the realm of cell and gene treatments for serious conditions like cancer. Founded in 2016 and headquartered in San Francisco, California, Vineti offers a cloud-based platform known as the Personalized Therapy Management (PTM) platform. This platform integrates various aspects of the therapeutic supply chain, including operations, manufacturing, quality assurance, and regulatory compliance, to streamline and automate processes. It addresses critical challenges faced by patients, healthcare providers, pharmaceutical companies, and regulatory bodies in the commercialization of personalized medicine. By enhancing supply chain orchestration and ensuring compliance with regulatory standards, Vineti aims to expand patient access to innovative therapies. The company also maintains regional offices in Bethesda, Maryland, and Yerevan, Armenia.

Founded in 2012, Geneticure develops pharmacogenetic testing tools that enable healthcare providers to offer personalized medicine. Its flagship product is a cheek-swab test predicting individual responses to high blood pressure medications and devices.

Unity Biotechnology is a biotechnology company dedicated to developing therapeutics that prevent, halt, or reverse age-related diseases. Its primary focus involves targeting senescent cells, designing senolytic medicines to clear these cells from the body while leaving normal cells unaffected. The company's pipeline includes UBX1325 for age-related eye diseases like diabetic macular edema.

Helix is a prominent population genomics company that focuses on the convergence of clinical care, research, and genomics. Its comprehensive platform assists health systems, life sciences companies, and payers in advancing genomic research and integrating genomic data into clinical practice. Helix operates one of the world's largest CLIA/CAP-certified next-generation sequencing labs and utilizes its proprietary Exome+ assay to support various aspects of population genomics, including participant recruitment, disease screening, result reporting, and both basic and translational research.

Eko Health is a leading digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others. For more information visit www.ekohealth.com.

Helixis, Inc. is a company that develops low-cost molecular diagnostic products.

Progentec Diagnostics, Inc. is a company focused on developing innovative diagnostic tests for managing systemic lupus erythematosus (SLE). Established in 2015 and headquartered in Oklahoma City, Oklahoma, the company has created the aiSLE DX platform, which offers tools like a flare prediction score to measure disease activity in SLE patients and an early diagnostic test for lupus. Progentec integrates advanced technology and collaborates with research institutions globally, aiming to address significant unmet needs in diagnostic interventions. The company's mission centers on improving disease management and reducing disease incidence through enhanced screening and early detection.

Unity Biotechnology is a biotechnology company dedicated to developing therapeutics that prevent, halt, or reverse age-related diseases. Its primary focus involves targeting senescent cells, designing senolytic medicines to clear these cells from the body while leaving normal cells unaffected. The company's pipeline includes UBX1325 for age-related eye diseases like diabetic macular edema.

Qrativ Inc., established in 2017 and headquartered in Cambridge, Massachusetts, specializes in developing an AI-driven healthcare platform focused on identifying potential treatments for rare diseases. The company's core product is a drug purposing platform designed to revolutionize how therapies for unmet medical needs are discovered and developed. This platform, Darwin.ai, employs machine learning and artificial intelligence to uncover new uses for existing molecules, aiming to provide treatments for conditions where market-available drugs are lacking. Qrativ serves biotechnology and pharmaceutical companies with this innovative solution.

Evelo Biosciences, Inc., established in 2015, is a biotechnology company based in Cambridge, Massachusetts. It specializes in the discovery and development of a novel class of medicines known as monoclonal microbials, which are orally delivered and designed to modulate systemic immunology and biology by interacting with human cells in the gut. Evelo's pipeline includes EDP1815, currently in a Phase 1b clinical trial for psoriasis and atopic dermatitis, and EDP1503, in a Phase 1/2 study for various cancer types, including colorectal, triple-negative breast, and melanoma. The company aims to apply this innovative approach across a broad range of diseases, including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory conditions, and cancer.

DayTwo Ltd. is a precision nutrition company based in Tel Aviv-Yafo, Israel, that focuses on leveraging gut microbiome analysis to provide tailored health solutions for metabolic diseases such as diabetes, prediabetes, clinical obesity, and non-alcoholic fatty liver disease (NAFLD). Founded in 2015, DayTwo utilizes a web-based platform that offers personalized dietary recommendations through its innovative Food Prescriptions™, which are designed to help individuals manage their blood sugar levels and improve overall health. By sequencing gut microbiomes, the company identifies how different foods affect each person, allowing for customized nutrition plans. DayTwo's virtual care model is supported by Certified Diabetes Care and Education Specialists and Registered Dietitians, who engage with patients through a smartphone application to track progress and ensure adherence to the dietary recommendations.

Glooko develops a remote patient-monitoring platform for individuals with diabetes. It integrates with diabetes devices, fitness wearables, and activity trackers to capture data and provide reports, aiming to drive behavior change and improve health outcomes. The platform facilitates communication between patients and healthcare providers, enhancing care. Glooko is available on Android and iOS.

Vineti, Inc. is a technology company focused on advancing the development and delivery of personalized therapies, particularly in the realm of cell and gene treatments for serious conditions like cancer. Founded in 2016 and headquartered in San Francisco, California, Vineti offers a cloud-based platform known as the Personalized Therapy Management (PTM) platform. This platform integrates various aspects of the therapeutic supply chain, including operations, manufacturing, quality assurance, and regulatory compliance, to streamline and automate processes. It addresses critical challenges faced by patients, healthcare providers, pharmaceutical companies, and regulatory bodies in the commercialization of personalized medicine. By enhancing supply chain orchestration and ensuring compliance with regulatory standards, Vineti aims to expand patient access to innovative therapies. The company also maintains regional offices in Bethesda, Maryland, and Yerevan, Armenia.

AliveCor, Inc. specializes in developing digital medical-grade electrocardiograms, enabling users to monitor their heart health through mobile technology. The company's flagship product, KardiaMobile, is a personal mobile EKG device that provides instant detection of common heart arrhythmias, along with features for blood pressure and weight tracking, as well as storage for recorded EKGs. Additionally, AliveCor offers KardiaMobile 6L, a six-lead EKG device that allows patients to share detailed EKG readings with healthcare providers. The company also operates KardiaCare, a digital health subscription service that empowers users to manage their heart health conveniently at home. Founded in 2010 and incorporated in 2011, AliveCor is headquartered in Mountain View, California, and is recognized for its innovative contributions to cardiac care through the integration of machine learning techniques.

Sensely is a developer of a conversational platform that enhances the experience of insurance plan members and patients through avatar and chatbot technology. The company offers virtual assistant solutions tailored for insurance companies, pharmaceutical clients, and hospital systems globally. By leveraging conversational interfaces, Sensely enables these organizations to engage with their members in a way that merges the empathy of human interaction with the efficiency and scalability of technological solutions. This approach aims to elevate brand preference and influence member behavior, ultimately improving overall healthcare communication.

Unity Biotechnology is a biotechnology company dedicated to developing therapeutics that prevent, halt, or reverse age-related diseases. Its primary focus involves targeting senescent cells, designing senolytic medicines to clear these cells from the body while leaving normal cells unaffected. The company's pipeline includes UBX1325 for age-related eye diseases like diabetic macular edema.